KRAS and neoplasm: However, Ki67 staining was clearly decreased all three tumor types upon treatment with C-PIK3CA-esiRNA treatment (Fig 3C, 3G and 3K) as well as in the combination group which received C-KRAS/PIK3CA-esiRNA complexes (Fig 3D, 3H and 3L).